About ten years ago Kiemeney and colleagues (2008) published the first genomewide association study (GWAS) discovering two novel single nucleotide polymorphisms (SNPs) near MYC (rs9642880) and TP63 (rs710521) associated with urinary bladder cancer (UBC) risk. Meanwhile, further GWAS and candidate gene studies identified and confirmed a number of susceptibility variants for UBC (Selinski, 2012 (Selinski, , 2013 (Selinski, , 2014 Dudek et al., 2013; Selinski et al., 2013; Golka et al., 2011) . Currently, fifteen genomic regions seem to play a major role in development of this disease (Table 1) . It can be assumed that almost all relevant polymorphisms have been discovered now. The most recent UBC GWAS of Figueroa et al. (2016) required 15,058 cases and 286,270 controls to discover a further susceptibility region at 13q34 (MCF2L gene), including the Icelandic and the Dutch GWAS (Gudbjartsson et al., 2015; Kiemeney et al., 2008) . The odds ratios of the most recent UBC risk SNPs are rather small, e.g. the MCF2L intron variant rs4907479, with the strongest signal in the 2016 fine-mapping study of Figueroa et al. (2016) resulted in an odds ratio (OR) of 1.13.
Several UBC risk variants are particularly relevant in persons exposed to bladder carcinogens -mainly by tobacco smoke (Burger et al., 2013; Garcia-Closas et al., 2005 , 2013 Selinski et al., 2013; Moore et al., 2011) but also by occupation and environment (Ebbinghaus et al., 2017; Höhne et al., 2017; Krech et al., 2017; Lukas et al., 2017; Carreón et al., 2014; Golka et al., , 2009 Golka et al., , 2004 Golka et al., , 2002 Golka et al., , 1997 Golka et al., , 1996 Delclos and Lerner, 2008; Rushton et al., 2012) . However, currently no particular variant that is only relevant in exposed persons could be identified and replicated in GWAS. In 2014, Figueroa et al. (2014a) identified two variants in a genome-wide smoking  SNP interaction study -rs1711973 (FOXF2) relevant for never smokers and rs12216499 (RSPH2-TAGAP-EZR) in ever smokers, but both could not be confirmed using a large replication series (Figueroa et al., 2016) . Nevertheless, interaction analyses and stratification regarding smoking habits and cancer invasiveness are promising future approaches to uncover further susceptibility variants that are relevant for particular subgroups of the UBC patients.
A further challenge is a genome-wide search for variants associated with bladder cancer recurrence and progression. This requires a large number of UBC patients with follow-up of several years after first diagnosis. However, it can be assumed that variants relevant for UBC development are also associated with UBC recurrence. Recurrence of this tumor occurs in approximately half of the patients with a median recurrence-free time of almost one year. Selinski et al. (2017a) showed that the ultra-slow Nacetyltransferase 2 (NAT2) genotype was associated with a significant reduction of recurrence-free time (8.4 months) compared to rapid acetylators (11 months) and an increased recurrence risk (66 % vs. 50 %, OR=1.89, 95 % CI = 1.06-3.38). Effects were more pronounced in ultra-slow smokers (7.9 months, 73 %) indicating the relevance of gene-environment interaction also for prognosis. Correspondingly, Lukas et al. (2017) showed in a series of 143 UBC cases with suspected occupational bladder cancer the importance of co-occurring susceptibility variants, particularly co-occurring GSTM1 negative and rs11892031[A/A] for UBC recurrence. They discovered that UBC cases with an elevated number of risk alleles had a significantly shorter median relapse-free time of 8 months compared to cases with few risk alleles.
According to the different importance of several genetic variants depending on exposure to bladder carcinogens, e.g. GSTM1 and NAT2, different variant combinations seem to play a major role in smokers and never smokers (Selinski et al., 2017b; Schwender et al., 2012 . Recently, Selinski et al. (2017b identified and replicated in a large multicentric case-controls series (discovery series: 2969 cases / 3285 controls, replication series: 2080 cases / 2167 controls) four-variant combinations out of twelve well-known UBC risk variants. The highest odds ratios were found in never smokers with the best combination
resulting in an OR of 2.59 (95 % CI = 1.93-3.47; P = 1.87 × 10 -10 , frequency in never smoking cases: 25 %). Odds ratios of the best combinations found in smokers were clearly lower (current smokers: 1.56, former: 2.13, ever: 1.55) and different variant combinations were relevant, especially GSTM1, rs1058396 (SLC14A1) and rs11892031 (UGT1A) combinations in current and rs9642880 (MYC), rs1495741 (NAT2) and rs8102137 (CCNE1) combinations in former smokers (Selinski et al., 2017b) . Table 1 : Currently confirmed polymorphisms that are associated with UBC risk, their association with bladder carcinogen exposure and prognosis (update of Selinski, 2014) according to Selinski (2014) . Polymorphisms, associated genes and locations are printed in bold, risk alleles or genotypes are given in brackets.
Location Gene(s)
Key message Reference
GSTM1 null was confirmed as risk factor for increased UBC risk in a GWAS (OR=1.47).
Rothman et al.
(2010) GSTM1 null was associated with recurrence (GSTM1*present/null HR=1.5, GSTM1*null/null HR=2.0 vs. GSTM1*present/present) and mortality (GSTM1*null/null vs. GSTM1* present/null HR=1.9) in the Copenhagen City Heart Study (CCHS).
Nørskov et al. (2011)
GSTM1 null × Smoking (additive interaction) was associated with increased UBC risk (ORSNP×Smoking=4.69, Paddi- 
Rothman et al. (2010)
Rs1495741[A/A] showed a very good specificity (94 %) for the prediction of the NAT2 phenotype. However, a perfect specificity was obtained by the common 7-SNPs NAT2 genotype (1.00) and a 2-SNPs genotype (1.00) based on the estabished 7 NAT2 SNPs in Caucasians. 
Wu et al. (2009)

Rs2978974[A]
(in an alternative untranslated 1 st exon of PSCA) was detected in a fine-mapping study (OR=1.11) and showed a significant interaction effect (P=0.035) with rs2294008 (10 kb upstream rs2978974) instead of capturing the same signal. 
Fu et al. (2012)
Rs2294008[T] × Smoking
Kiemeney et al. (2008) Rs9642880[T]
UBC risk was less pronounced in cases with suspected exposure to bladder carcinogens (OR=1.04 and 1.11 exposed study groups) than in non-exposed persons (OR=1.36) in contrast to GSTM1 null (OR=2.43 and 1.38 in exposed study groups, OR=1.22 non-exposed persons). Rafnar et al. (2014) Rs6108803 (intergenic, 300 kb of JAG1) was associated with UBC in a fine-mapping study (OR=1.18) and explained most of the effect of rs62185668 (Padj=0.25). The effect of rs6104690 (OR=1.11) could be confirmed in 8,147 additional cases and 274,456 controls (in total: 15,058 / 286,270) compared to Figueroa et al. (2014b) . Rs6108803-rs6104690 haplotypes had a maximum OR=1.21, indicating that the signal in 20p12.2 can be captured by these two SNPs. The association with MIBC was stronger than with NMIBC for rs6108803 (ORMIBC= 1.36, ORNMIBC=1.10, POR difference=0.02) and rs62185668 (ORMIBC= 1.39, ORNMIBC=1.13, POR difference=0.01) but not for rs6104690 (ORMIBC= 1.22, ORNMIBC=1.10, POR difference=0.20 
Rs1014971[T]
(intergenic, 25 kb from CBX6, 64 kb from APOBEC3A) was associated with UBC in a GWAS (OR=1.14). 
Garcia-Closas et al. (2013)
Rs1014971 was not associated with UBC prognosis.
Grotenhuis et al.
(2014) Rs1014971 UBC risk could not be confirmed in a Chinese study group (1050 cases, 1404 controls, OR=1.14, P=0.050). Wang et al. (2014) OR: odds ratio, P: P value, HR: hazard ratio, 95 % CI: 95 % confidence interval, adj.: adjusted NMIBC: non-muscle invasive bladder cancer, MIBC: muscle-invasive or metastatic bladder cancer, PAHs: polycyclic aromatic hydrocarbons
